Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Kodiak Sciences Inc KOD

Healthcare Biotechnology
Kodiak Sciences Inc. is a biopharmaceutical company. The Company has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) Platform, for retinal medicines. Its ABC Platform uses molecular engineering to merge the fields of protein-based and chemistry-based therapies. Its lead investigational medicine, tarcocimab, is a novel anti-vascular endothelial growth factor (anti-VEGF) antibody biopolymer conjugate under development for the treatment of high prevalence retinal vascular diseases, including diabetic retinopathy, the cause of blindness in working-age patients in the developed world, and wet age-related macular degeneration, the cause of blindness in elderly patients. Its second investigational medicine, KSI-501, is a bispecific antibody biopolymer conjugate targeting the pro-inflammatory cytokine interleukin-6 (IL-6) and VEGF. It is also developing a third investigational medicine, KSI-101, an unconjugated bispecific protein targeting IL-6 and VEGF.


NDAQ:KOD - Post by User

Kodiak Sciences Inc
Bullboard Posts
Next >>
User Avatar Image
(4)
•••
Post by AviseAnalyticson Feb 25, 2022 7:07am
165 Views
Post# 34460660

THE UNRAVELLING OF KODIAK SCIENCES

THE UNRAVELLING OF KODIAK SCIENCES
$KOD
 
Kodiak Sciences, Inc. (NASDAQ: KOD), a clinical-stage biotechnology Company focused on creating novel therapeutics for the treatment of retinal diseases announced disappointing results from a Phase 2b/3 clinical trial evaluating KSI-301, a novel antibody biopolymer conjugate, intended for the treatment of neovascular (wet) age-related macular degeneration. 
 
The stock of the Company has plummeted by 80% in the aftermath of the news.
 
 
https://www.aviseanalytics.com/the-unravelling-of-kodiak-sciences/
 
Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities